Loading…
Trulieve Cannabis Corp.
Trulieve Cannabis Corp. (TRLV) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Tallahassee, United States and has 5,000 employees. The company is worth $1.93B. Revenue was $1.18B in fiscal 2025, down 0.4% from the year before. It reported a net loss of $122.25M. The share price is 24.6% below its 52-week high of $13.28. None of the 38 superinvestors we track reported it in their latest 13F. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in TRLV.
▼ -62.5% over 5Y.
today you would have $397.70▼ -60.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.69 | $5.18 | $5.21 | $7.57 | $26.01 | $31.62 | $11.84 | |
| P/E | 59.7x | — | — | — | — | 123.9x | 59.7x | 25.7x |
| P/S | 1.4x | 1.4x | 0.8x | 0.9x | 1.2x | 5.0x | 7.2x | 5.4x |
| P/B |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XNCRXencor Inc | $25.84 | — | 3.8x | 0.00% | -29.07% | $1.92B |
| SRPTSarepta Therapeutics, Inc. | $18.18 | — | 1.3x | 0.00% | -9.48% | $1.92B |
| RXRXRecursion Pharmaceuticals Inc | $3.58 | — | 2.1x | 0.00% | -56.58% | $1.92B |
| LMATLemaitre Vascular Inc | $85.33 |
| 1.5x |
| 1.5x |
| 0.8x |
| 0.7x |
| 0.7x |
| 2.2x |
| 8.4x |
| 10.3x |
| EPS | -$0.58 | -$0.79 | -$2.28 | -$0.95 | $0.21 | $0.53 | $0.46 |
| Profit margin | -10.35% | -10.35% | -13.53% | -47.21% | -20.75% | 1.87% | 12.08% | 21.00% |
| ROE | -10.70% | -10.70% | -12.86% | -37.85% | -13.11% | 0.81% | 14.07% | 39.96% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
2 methods answered, across 2 families.
Room for errors in the reported numbers.
+98.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 29.9x |
| 4.6x |
| 1.17% |
| 16.77% |
| $1.95B |
| MLYSMineralys Therapeutics, Inc. | $21.47 | — | 3.4x | 0.00% | -80.88% | $1.9B |
| XRAYDENTSPLY SIRONA Inc. | $9.50 | — | 1.4x | 1.68% | -33.03% | $1.89B |